{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:53Z","timestamp":1792801793757,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/leu.2017.29","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T02:41:53Z","timestamp":1484880113000},"page":"2094-2103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":636,"title":["Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma"],"prefix":"10.1038","volume":"31","author":[{"given":"J","family":"Flores-Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sanoja-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V H J","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"P\u00e9rez-Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-B","family":"Vidriales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Corral-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G-E","family":"Grigore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Flux\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Caetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sedek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-C","family":"del Ca\u00f1izo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"B\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Leoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Aguilera-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-V","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J M","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"BFleu201729_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/leu.2013.350","volume":"28","author":"EM Ocio","year":"2014","unstructured":"Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525\u2013542.","journal-title":"Leukemia"},{"key":"BFleu201729_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","volume":"126","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Richardson PG, Anderson KC . Promising therapies in multiple myeloma. Blood 2015; 126: 300\u2013310.","journal-title":"Blood"},{"key":"BFleu201729_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2015.223","volume":"30","author":"S Lonial","year":"2016","unstructured":"Lonial S, Durie B, Palumbo A, San-Miguel J . Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 2016; 30: 526\u2013535.","journal-title":"Leukemia"},{"key":"BFleu201729_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101\u2013119.","journal-title":"Mayo Clin Proc"},{"key":"BFleu201729_CR5","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"JJ Lahuerta","year":"2008","unstructured":"Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775\u20135782.","journal-title":"J Clin Oncol"},{"key":"BFleu201729_CR6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279\u20133287.","journal-title":"J Clin Oncol"},{"key":"BFleu201729_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226\u2013232.","journal-title":"Leukemia"},{"key":"BFleu201729_CR8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014; 32: 634\u2013640.","journal-title":"J Clin Oncol"},{"key":"BFleu201729_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1586\/17474086.2014.864230","volume":"7","author":"MV Mateos","year":"2014","unstructured":"Mateos MV, Leleu X, Palumbo A, San Miguel JF . Initial treatment of transplant-ineligible patients in multiple myeloma. Expert Rev Hematol 2014; 7: 67\u201377.","journal-title":"Expert Rev Hematol"},{"key":"BFleu201729_CR10","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M . Multiple myeloma. Lancet 2015; 385: 2197\u20132208.","journal-title":"Lancet"},{"key":"BFleu201729_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","volume":"29","author":"MV Mateos","year":"2015","unstructured":"Mateos MV, Ocio EM, Paiva B, Rosinol L, Martinez-Lopez J, Blade J et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev 2015; 29: 387\u2013403.","journal-title":"Blood Rev"},{"key":"BFleu201729_CR12","doi-asserted-by":"publisher","first-page":"832049","DOI":"10.1155\/2015\/832049","volume":"2015","author":"M Fulciniti","year":"2015","unstructured":"Fulciniti M, Munshi NC, Martinez-Lopez J . Deep response in multiple myeloma: a critical review. BioMed Res Int 2015; 2015: Article ID 832049.","journal-title":"BioMed Res Int"},{"key":"BFleu201729_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2013.220","volume":"28","author":"S Lonial","year":"2014","unstructured":"Lonial S, Anderson KC . Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014; 28: 258\u2013268.","journal-title":"Leukemia"},{"key":"BFleu201729_CR14","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025\u20133031.","journal-title":"Blood"},{"key":"BFleu201729_CR15","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J . Curing myeloma at last: defining criteria and providing the evidence. Blood 2014; 124: 3043\u20133051.","journal-title":"Blood"},{"key":"BFleu201729_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A . New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015; 125: 3059\u20133068.","journal-title":"Blood"},{"key":"BFleu201729_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687\u2013691.","journal-title":"Blood"},{"key":"BFleu201729_CR18","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29: 1627\u20131633.","journal-title":"J Clin Oncol"},{"key":"BFleu201729_CR19","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2014-04-567909","volume":"124","author":"B Paiva","year":"2014","unstructured":"Paiva B, Montalb\u00e1n MA, Puig N, Cordon L, Martinez-Lopez J, Ocio EM et al. Clinical significance of sensitive Flow-MRD monitoring in elderly multiple myeloma patients on the Pethema\/GEM2010MAS65 Trial. Blood 2014; 124: 3390.","journal-title":"Blood"},{"key":"BFleu201729_CR20","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540\u20132547.","journal-title":"J Clin Oncol"},{"key":"BFleu201729_CR21","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","volume":"100","author":"AC Rawstron","year":"2002","unstructured":"Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100: 3095\u20133100.","journal-title":"Blood"},{"key":"BFleu201729_CR22","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015; 125: 1932\u20131935.","journal-title":"Blood"},{"key":"BFleu201729_CR23","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1038\/bcj.2013.33","volume":"3","author":"N Robillard","year":"2013","unstructured":"Robillard N, Bene MC, Moreau P, Wuilleme S . A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013; 3: e134.","journal-title":"Blood Cancer J"},{"key":"BFleu201729_CR24","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 2016; 127: 3165\u20133174.","journal-title":"Blood"},{"key":"BFleu201729_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014; 28: 391\u2013397.","journal-title":"Leukemia"},{"key":"BFleu201729_CR26","first-page":"1365","volume":"90","author":"ME Sarasquete","year":"2005","unstructured":"Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365\u20131372.","journal-title":"Haematologica"},{"key":"BFleu201729_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241\u2013253.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu201729_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejh.12000","volume":"89","author":"N Puig","year":"2012","unstructured":"Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillon MC, Sebastian E et al. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. Eur J Haematol 2012; 89: 328\u2013335.","journal-title":"Eur J Haematol"},{"key":"BFleu201729_CR29","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073\u20133079.","journal-title":"Blood"},{"key":"BFleu201729_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286\u2013295.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201729_CR31","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328\u2013e346.","journal-title":"Lancet Oncol"},{"key":"BFleu201729_CR32","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257\u20132317.","journal-title":"Leukemia"},{"key":"BFleu201729_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014; 28: 1299\u20131307.","journal-title":"Leukemia"},{"key":"BFleu201729_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-016-0336-4","volume":"9","author":"Y Bai","year":"2016","unstructured":"Bai Y, Wong KY, Fung TK, Chim CS . High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers\/probes. J Hematol Oncol 2016; 9: 107.","journal-title":"J Hematol Oncol"},{"key":"BFleu201729_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjh.12576","volume":"163","author":"J Martinez-Lopez","year":"2013","unstructured":"Martinez-Lopez J, Fernandez-Redondo E, Garcia-Sanz R, Montalban MA, Martinez-Sanchez P, Pavia B et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM\/PETHEMA study. Br J Haematol 2013; 163: 581\u2013589.","journal-title":"Br J Haematol"},{"key":"BFleu201729_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cyto.b.21271","volume":"90","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, de Tute RM, Haughton J, Owen RG . Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the leeds haematological malignancy diagnostic service. Cytometry B Clin Cytom 2016; 90: 54\u201360.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR37","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A . Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015; 125: 3996\u20134009.","journal-title":"Blood"},{"key":"BFleu201729_CR38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","volume":"122","author":"A Flanders","year":"2013","unstructured":"Flanders A, Stetler-Stevenson M, Landgren O . Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 2013; 122: 1088\u20131089.","journal-title":"Blood"},{"key":"BFleu201729_CR39","doi-asserted-by":"publisher","first-page":"E502","DOI":"10.1002\/ajh.24540","volume":"91","author":"D Salem","year":"2016","unstructured":"Salem D, Stetler-Stevenson M, Yuan C, Landgren O . Myeloma minimal residual disease testing in the United States: evidence of improved standardization. Am J Hematol 2016; 91: E502\u2013E503.","journal-title":"Am J Hematol"},{"key":"BFleu201729_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.21249","volume":"90","author":"M Stetler-Stevenson","year":"2016","unstructured":"Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom 2016; 90: 26\u201330.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431\u2013438.","journal-title":"Haematologica"},{"key":"BFleu201729_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom 2016; 90: 31\u201339.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/cyto.a.20608","volume":"73","author":"CE Pedreira","year":"2008","unstructured":"Pedreira CE, Costa ES, Barrena S, Lecrevisse Q, Almeida J, van Dongen JJ et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A 2008; 73: 834\u2013846.","journal-title":"Cytometry A"},{"key":"BFleu201729_CR44","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986\u20132010.","journal-title":"Leukemia"},{"key":"BFleu201729_CR45","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908\u20131975.","journal-title":"Leukemia"},{"key":"BFleu201729_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.tibtech.2013.04.008","volume":"31","author":"CE Pedreira","year":"2013","unstructured":"Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A, EuroFlow C . Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 2013; 31: 415\u2013425.","journal-title":"Trends Biotechnol"},{"key":"BFleu201729_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cyto.a.20092","volume":"62","author":"HT Maecker","year":"2004","unstructured":"Maecker HT, Frey T, Nomura LE, Trotter J . Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 2004; 62: 169\u2013173.","journal-title":"Cytometry A"},{"key":"BFleu201729_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016; 90: 61\u201372.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR49","unstructured":"Orfao De Matos Correia, e Vale A, Sobral da Costa E, Pedreira CE Method for the multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry, European patent 1724581B1 (2014)."},{"key":"BFleu201729_CR50","unstructured":"Orfao De Matos A, Pedreira CE, Sobral Da Costa E Generation of flow cytometry datafiles with a potentially infinite number of dimensions derived from the fusion of a group of separate flow cytometry datafiles and their multidimensional reconstruction with both actually measured and estimated flow cytometry data, European patent EP1770387B1 (2011)."},{"key":"BFleu201729_CR51","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/cyto.a.20638","volume":"73A","author":"CE Pedreira","year":"2008","unstructured":"Pedreira CE, Costa ES, Almeida J, Fernandez C, Quijano S, Flores J et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008; 73A: 1141\u20131150.","journal-title":"Cytometry A"},{"key":"BFleu201729_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cyto.b.21269","volume":"90","author":"F Pojero","year":"2016","unstructured":"Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B et al. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom 2016; 90: 91\u2013100.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR53","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-14-2841","volume":"21","author":"B Paiva","year":"2015","unstructured":"Paiva B, Puig N, Garcia-Sanz R, San Miguel JF . Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res 2015; 21: 2001\u20132008.","journal-title":"Clin Cancer Res"},{"key":"BFleu201729_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21272","volume":"90","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Paiva B, Stetler-Stevenson M . Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom 2016; 90: 21\u201325.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR55","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1038\/bcj.2014.69","volume":"4","author":"R Silvennoinen","year":"2014","unstructured":"Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J 2014; 4: e250.","journal-title":"Blood Cancer J"},{"key":"BFleu201729_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cyto.b.21239","volume":"90","author":"BL Wood","year":"2016","unstructured":"Wood BL . Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 2016; 90: 47\u201353.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu201729_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ajcp\/aqw052","volume":"146","author":"DJ Royston","year":"2016","unstructured":"Royston DJ, Gao Q, Nguyen N, Maslak P, Dogan A, Roshal M . Single-Tube 10-fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma. Am J Clin Pathol 2016; 146: 41\u201349.","journal-title":"Am J Clin Pathol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201729","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu201729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:10:08Z","timestamp":1684419008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFleu201729"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.29","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"18 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G-EG and RF are employees of Cytognos SL, Salamanca, Spain. JJMvD received research support and traveling support from Roche, Amgen and Becton Dickinson. SB received research support from Roche, Celgene, Becton Dickinson and AbbVie as well as honoraria from Roche and AbbVie. JF-M, LS-F, OG-S, J-JP-M, AC-M, CJ, JM-L, M-VM, VvdV, JC, LS, NP, M-BV, RGS, MG, RP, M-CdC, JB, J-JL, CA, AB, AG-M, JL, PL, CA-S, JS-M, BD and AO declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}